Sun Pharma Q3 Results: Profit Increases to Rs 914 crore with 26%

Sun Pharma Q3 Results: Profit Increases to Rs 914 crore with 26%:

Sun Pharma Q3 Results: Profit Increases to Rs 914 crore with 26%:

Sun Pharma Q3 Results: Profit Increases to Rs 914 crore with 26%:

Sun Pharma Q3 Results: Sun pharma is a multinational pharmaceutical company in Mumbai. It manufactures and sells medicines in India and Us. On Thursday, the company reported a 26.43% fall in YoY to the consolidated net profit of Rs 913.52 crore against the previous amount of Rs 1,241.85 crore in the same period last fiscal year.

However, the companies revenue growth increased to 4.98% of Rs 8,038.65 crore against the previous amount of Rs 7,656.71 crore in the same period of last fiscal year. The board of the company announced an equity dividend of Rs 3 per share on Thursday.

Whereas, the company’s earnings before interest, tax, depreciation, and amortization (EBITDA) margin measures at 21.5%. while the company’s net profit margin at 11.4%. For Research and Development(R&D), the company invested an amount of Rs 527 crore against Rs 465 crore in the same period the previous year.

The company sales for this quarter in India stand at Rs 2,517 crore with a 13% increase. Whereas in the US, the sales of the company stand at $350million with a 3% decrease. Coming to emerging market sales the company stand at $195 million with a 4% decrease. The remaining countries the company sales at $155 million with a 24% increase YoY.

The company MD Mr. Dilip Shanghvi said, “the company business in India is doing really well and has reported double-digit growth for this quarter. Whereas the International business, we are trying to enter into the new market with AstraZeneca in China. Simultaneously, we are trying to expand our business globally for the companies overall growth.

 

 

 

0 Reviews

Write a Review

Read Previous

YES Bank share price increase 5.16% to Rs 40.70 crore: Stock

Read Next

M&M share price drop to 6%: Top loser of today’s Sensex, Nifty

Translate »